查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1521007

動物 API 市場 – 2024 年至 2029 年預測

Veterinary Api Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

動物 API 市場預計將從 2024 年的估計值79.25 億美元成長到 2029 年的 117.94 億美元，複合年成長率為 8.28%。

獸醫學的進步、寵物擁有量的增加以及對獸醫保健產品不斷成長的需求是獸藥 API（活性藥物成分）市場快速成長的驅動力。在治療動物的各種健康狀況時，原料藥至關重要。由於動物福利意識的增強、監管支持和技術改進等關鍵因素，市場正在不斷擴大。

市場擴張的進一步驅動力是收養伴同性動物作為家庭成員以及創新替代療法的開發。動物原料藥市場專注於改善動物健康和福利，處於持續創新和發展的有利地位，以滿足不斷變化的行業需求。

動物原料藥市場的促進因素：

  • 越來越多的寵物主人預計將加強動物 API 市場。

動物保健產品市場，尤其是那些依賴原料藥的市場，受到寵物飼養量增加的推動。越來越多的家庭將寵物視為家庭成員，這推動了對藥物、注射和治療的需求。這一趨勢推動了對滿足不同動物物種醫療保健需求的多樣化 API 的需求。獸醫學的進步和狗飼主對狗的健康所做的大量投資刺激了 API 開發的創新。

此外，寵物的人性化正在提高尖端醫療保健的標準，並推動獸醫原料藥市場的成長，以滿足飼主不斷變化的需求。目前的法律規範營造了有利於體外毒性測試行業擴張的氛圍。

根據美國獸醫協會的數據，2021年，狗和貓的數量增加，養狗和貓的家庭比例也增加，但每戶平均寵物數量減少。新購買的寵物很大一部分來自動物收容所，2020 年，38% 的狗和 40% 的貓來自動物收容所。養狗率從年終的38%提高到2020年的45%。 2016年終寵物狗數量預計將從8,370萬隻增加到8,890萬隻，增幅9%到16%。 2020年，養貓家庭數量比2016年終增加了26%。寵物貓的數量預計將從五年前的 5,840 萬隻增加到去年的 6,190 萬隻。

  • 技術進步預計將推動動物原料藥市場的成長。

獸用原料藥市場是由獸藥技術開拓驅動的，例如創新的劑量方法和精準醫療方法。藥物基因體學、生物技術和奈米技術的進步使得更精確、更有效的動物用藥品的開發成為可能。獸醫和寵物飼主的需求不斷變化，製造技術的改進正在以更有效率、更高品質的原料藥滿足他們的需求。這些新興市場的開拓將支持獸用原料藥市場的擴張和創新，不僅有助於生產更安全、更有效的藥物，還能改善動物健康。

2022年11月7日，印度領先的動物用藥品公司之一、對獸藥製劑和原料藥有著濃厚興趣的SeQuent Scientific Limited（SeQuent）收購了印度公司Tineta Pharma Private Limited（Tineta）100%的股份。達成了協議。 SeQuent 將印度定位為戰略市場，此次收購預計將顯著加速其在該國製劑業務的成長，這將受益於在家牛的更大影響力。收購價格為21.8億印度盧比，包括優先配發價值6.5億印度盧比的SeQuent股票和15.3億印度盧比的現金對價。

  • 寵物多樣化預計將推動動物原料藥市場的發展。

動物原料藥市場是由狗、貓、鳥類和爬蟲類等各類寵物的廣泛飼主所推動的。這些需求需要廣泛的藥物治療。這種需求正在推動特定原料藥的製造和創造，為多種動物創造強效藥物、疫苗和治療方法。為此，生產商正在開發新的原料藥滿足不同動物物種的獨特生理和藥物需求，推動動物用藥品產業的擴張。這種動態情況正在推動持續的研究和開發，以提高獸醫 API 的可用性和功效，以支持世界各地各種寵物的健康。

動物 API 市場 – 地理視角

  • 亞太地區預計將大幅成長。

亞太地區動物原料藥市場正在顯著成長。這一成長是由寵物飼養量增加、對動物健康的更好了解以及對高品質動物用藥品的需求不斷成長等因素所推動的。該地區蓬勃發展的畜牧業也推動了對動物原料藥的需求。市場成長是由政府支持動物健康和福利的計劃以及動物用藥品研究和開發的進步所推動的。由於中產階級的擴大和生活水準的提高，亞太地區的動物原料藥市場預計將繼續強勁開拓。

動物原料藥市場的限制因素：

  • 監管問題可能會限制動物 API 市場。

獸用原料藥業務的一個關鍵障礙是確保各地區的監管合規性。 FDA 和 EMA 等監管機構制定了獸用原料藥必須遵守的嚴格品質和安全要求。然而，這些要求因國家而異，給尋求出口的製造商帶來了挑戰。遵守各種法規會為製造過程帶來額外的複雜性，需要徹底的測試、記錄，有時還需要重新配製。有效克服這些監管障礙，同時保持產品品質和一致性仍然是動物原料藥市場中公司面臨的主要挑戰。

動物 API 市場的主要發展：

  • 2024 年 1 月 -美國食品藥物管理局發布產業指南草案。該指南草案的目的是為動物用藥品中使用的活性藥物原料藥(API) 的生產中的良好生產規範 (GMP) 提供提案。這有助於統一全球標準，對活性原料藥和動物用藥品原料生產設施進行 GMP 檢查。
  • 2023 年 1 月 - 為製藥業供應原料的 Ofichem Groep 收購了位於萊頓的學名藥製造商 InnoGenerics。衛生部也為重新開始提供了40萬歐元的擔保和額外的15,000歐元的支持。 InnoGenerics 生產治療多種疾病的非處方藥，包括癲癇、糖尿病、心臟病和憂鬱症。該公司每年生產超過 30 億片藥片。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章動物原料藥市場：依產品類型

  • 介紹
  • 驅蟲藥
    • 市場趨勢和機遇
    • 成長前景
  • 抗感染
    • 市場趨勢和機遇
    • 成長前景
  • 疫苗
    • 市場趨勢和機遇
    • 成長前景
  • NSAIDs
    • 市場趨勢和機遇
    • 成長前景
  • 其他
    • 市場趨勢和機遇
    • 成長前景

第6章動物原料藥市場：依服務類型

  • 介紹
  • 公司內部
    • 市場趨勢和機遇
    • 成長前景
  • 合約外包
    • 市場趨勢和機遇
    • 成長前景
    • 合約開發
    • 契約製造

第7章動物原料藥市場：依合成類型

  • 介紹
  • 基於 OMICS 化學的 API
    • 市場趨勢和機遇
    • 成長前景
  • 生物原料藥
    • 市場趨勢和機遇
    • 成長前景
  • 高效能 API (HPAPI)
    • 市場趨勢和機遇
    • 成長前景

第8章動物原料藥市場：依途徑

  • 介紹
  • 口服
    • 市場趨勢和機遇
    • 成長前景
  • 注射
    • 市場趨勢和機遇
    • 成長前景
  • 局部的
    • 市場趨勢和機遇
    • 成長前景
  • 其他
    • 市場趨勢和機遇
    • 成長前景

第9章動物原料藥市場：依地區

  • 介紹
  • 北美洲
    • 依產品類型
    • 按服務類型
    • 依成分類型
    • 依給藥途徑
    • 按國家/地區
  • 南美洲
    • 依產品類型
    • 按服務類型
    • 依成分類型
    • 依給藥途徑
    • 按國家/地區
  • 歐洲
    • 依產品類型
    • 按服務類型
    • 依成分類型
    • 依給藥途徑
    • 按國家/地區
  • 中東/非洲
    • 依產品類型
    • 按服務類型
    • 依成分類型
    • 依給藥途徑
    • 按國家/地區
  • 亞太地區
    • 依產品類型
    • 按服務類型
    • 依成分類型
    • 依給藥途徑
    • 按國家/地區

第10章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第11章 公司簡介

  • Sequent Scientific Ltd.（Alivira Animal Health Limited）
  • Stanley Black & Decker（Excel Industries Limited）
  • Ofichem Group
  • Menadiona
  • SUANFARMA
  • NGL Fine-Chem Ltd.
  • FIS-Fabbrica Italiana Sintetici SpA
  • Sidhiv Pharma
  • Chempro Pharma Private Limited
  • AMGIS Lifescience Ltd
簡介目錄
Product Code: KSI061616896

The Veterinary API market is projected to grow at a CAGR of 8.28% from estimated value of US$7.925 billion in 2024 to US$11.794 billion in 2029.

Advances in veterinary medicine, growing pet ownership, and the growing need for animal healthcare products are driving the veterinary API (Active Pharmaceutical Ingredient) market's rapid rise. When creating treatments for a range of animal health conditions, APIs are essential. The market is expanding due to important factors such as increased awareness about animal welfare, regulatory backing, and technology improvements.

Further driving market expansion are the introduction of companion animals as family members and the development of innovative therapeutic alternatives. With an emphasis on improving animal health and wellbeing, the veterinary API market is well-positioned for ongoing innovation and development to satisfy changing industry demands.

Veterinary API Market Drivers:

  • Increasing pet ownership is anticipated to bolster the veterinary API market.

The market for veterinary healthcare products, particularly those that depend on APIs, is driven by an increase in pet ownership. The number of homes adopting pets as family members is increasing, which drives up the demand for drugs, shots, and therapies. This trend increases the necessity for a variety of APIs catered to the healthcare requirements of different species. Innovation in API development is spurred by veterinary medicine's developments and the significant investment that pet owners make in their dogs' health.

The humanization of pets also raises the bar for cutting-edge medical care, which drives the veterinary API market's growth to satisfy pet owners' changing wants. The current regulatory framework fosters an atmosphere that is conducive to the expansion of the in-vitro toxicity testing industry.

According to the American Veterinary Medical Association, in 2021, the number of dogs and cats increased, as has the proportion of families with dogs or cats, although the average number of pets per household decreased. A significant portion of new pet purchases come from animal shelters; in 2020, 38% of dogs and 40% of cats came from them. Dog ownership increased to 45% of households in 2020 from 38% at the end of 2016. Between 83.7 million and 88.9 million dogs were predicted to be owned as pets at the end of 2016, an increase of 9%-16%. There were 26% more households with cats in 2020 than there were at the end of 2016. The number of pet cats was expected to be between 60 million and 61.9 million last year, up from 58.4 million five years earlier.

  • Technological advancements are expected to drive the veterinary API market growth.

The veterinary API market is being driven by technological developments in veterinary medicine, such as innovative medication delivery methods and precision medicine approaches. Developments in pharmacogenomics, biotechnology, and nanotechnology have made it possible to create veterinary medications that are more precise and efficacious. Veterinarians and pet owners have evolving demands, which are met by APIs produced with more efficiency and quality because of improved manufacturing techniques. These developments not only make it easier to produce safer and more effective drugs, but they also support the expansion and innovation of the veterinary API market, which improves animal health outcomes.

On November 07, 2022, a definitive agreement was reached by SeQuent Scientific Limited (SeQuent), the foremost animal health firm in India with a strong focus on veterinary formulations and APIs, to purchase a 100% share in Tineta Pharma Private Limited (Tineta), an Indian-incorporated company.SeQuent views India as a strategic market, and this acquisition was anticipated to significantly accelerate the growth of the country's formulations business, which benefits from having a larger presence in the cattle market. The transaction was valued at Rs. 218 crores, and the payment for it was made in the form of preferential allotment of SeQuent's equity shares worth Rs. 65 crores and cash consideration of Rs. 153 crores.

  • Diverse pet populations are anticipated to boost the veterinary API market.

The market for veterinary APIs is driven by the wide range of pet owners who own different species of dogs, cats, birds, and reptiles. These needs require a wide range of pharmaceutical treatments. This need drives the creation and manufacturing of specific APIs to create potent drugs, vaccinations, and therapies for many kinds of animals. In response, producers develop novel APIs to cater to the distinct physiological and medicinal needs of various animal species, hence propelling the veterinary pharmaceutical industry expansion. To support the health of different pets around the world, this dynamic landscape encourages ongoing research and development, improving the availability and effectiveness of veterinary APIs.

Veterinary API Market - Geographical Outlook

  • Asia Pacific region is expected to grow significantly.

The veterinary API market in the Asia-Pacific area has grown significantly. This growth has been driven by elements including an increase in pet ownership, a greater understanding of animal health, and a rising need for high-quality veterinary medications. The booming cattle industry in the area has also boosted demand for veterinary APIs. The market is growing because of government programs that support animal health and welfare as well as developments in veterinary medicine research and development. Shortly, the Asia-Pacific veterinary API market is anticipated to maintain its strong development trajectory due to the region's expanding middle class and rising living standards.

Veterinary API Market Restraints:

  • Regulatory concerns can constrain the market for veterinary API.

A significant obstacle in the veterinary API business is making sure regulations are followed in various geographical areas. Regulatory agencies such as the FDA, EMA, and others have strict quality and safety requirements that veterinary APIs must adhere to. However, these requirements might differ greatly between nations, which presents challenges for producers looking to export. Complying with various regulatory regulations introduces additional levels of complexity to the production process, necessitating thorough testing, documentation, and occasionally reformulation. For companies in the veterinary API market, overcoming these regulatory obstacles effectively while preserving product quality and consistency is still a major problem.

Veterinary API Market Key Development:

  • January 2024- U.S. Food and Drug Administration announced a draft guidance for the industry titled. This draft guidance's goal was to offer suggestions for good manufacturing practices (GMPs) in the production of active pharmaceutical ingredients (APIs), used in veterinary pharmaceuticals. It made it easier to harmonize a single set of global standards for GMP inspections of establishments producing APIs and raw ingredients for usage in such goods. Additionally, it gave producers and authorities a framework to guarantee that APIs fulfill the desired standards for quality and purity.
  • January 2023- Ofichem Groep, a provider of raw materials to the pharmaceutical sector, acquired Leiden-based generic drug manufacturer InnoGenerics.The health ministry also backed the relaunch with a €400,000 guarantee and an additional €15,000.InnoGenerics manufactures over-the-counter medications for a variety of illnesses, such as epilepsy, diabetes, heart disease, and depression. The company produced over three billion tablets annually in total.

Market Segmentation:

By Product Type

  • Antiparasitic
  • Anti-infectives
  • Vaccines
  • NSAIDs
  • Others

By Service Type

  • In House
  • Contract Outsourcing
  • Contract Development
  • Contract Manufacturing

By Synthesis Type

  • OMICS Chemical-Based API
  • Biological API
  • Highly Potent API (HPAPI)

By Route of administration

  • Oral
  • Injectable
  • Topical
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. VETERINARY API MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Antiparasitic
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
  • 5.3. Anti-infectives
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects
  • 5.4. Vaccines
    • 5.4.1. Market Trends and Opportunities
    • 5.4.2. Growth Prospects
  • 5.5. NSAIDs
    • 5.5.1. Market Trends and Opportunities
    • 5.5.2. Growth Prospects
  • 5.6. Others
    • 5.6.1. Market Trends and Opportunities
    • 5.6.2. Growth Prospects

6. VETERINARY API MARKET BY SERVICE TYPE

  • 6.1. Introduction
  • 6.2. In House
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
  • 6.3. Contract Outsourcing
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects
    • 6.3.3. Contract Development
    • 6.3.4. Contract Manufacturing

7. VETERINARY API MARKET BY SYNTHESIS TYPE

  • 7.1. Introduction
  • 7.2. OMICS Chemical Based API
    • 7.2.1. Market Trends and Opportunities
    • 7.2.2. Growth Prospects
  • 7.3. Biological API
    • 7.3.1. Market Trends and Opportunities
    • 7.3.2. Growth Prospects
  • 7.4. Highly Potent API (HPAPI)
    • 7.4.1. Market Trends and Opportunities
    • 7.4.2. Growth Prospects

8. VETERINARY API MARKET BY ROUTE OF ADMINISTRATION

  • 8.1. Introduction
  • 8.2. Oral
    • 8.2.1. Market Trends and Opportunities
    • 8.2.2. Growth Prospects
  • 8.3. Injectable
    • 8.3.1. Market Trends and Opportunities
    • 8.3.2. Growth Prospects
  • 8.4. Topical
    • 8.4.1. Market Trends and Opportunities
    • 8.4.2. Growth Prospects
  • 8.5. Others
    • 8.5.1. Market Trends and Opportunities
    • 8.5.2. Growth Prospects

9. VETERINARY API MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product Type
    • 9.2.2. By Service Type
    • 9.2.3. By Synthesis Type
    • 9.2.4. By Route of Administration
    • 9.2.5. By Country
      • 9.2.5.1. United States
        • 9.2.5.1.1. Market Trends and Opportunities
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Trends and Opportunities
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Trends and Opportunities
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Product Type
    • 9.3.2. By Service Type
    • 9.3.3. By Synthesis Type
    • 9.3.4. By Route of Administration
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Trends and Opportunities
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Trends and Opportunities
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Trends and Opportunities
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Product Type
    • 9.4.2. By Service Type
    • 9.4.3. By Synthesis Type
    • 9.4.4. By Route of Administration
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
        • 9.4.5.1.1. Market Trends and Opportunities
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. Germany
        • 9.4.5.2.1. Market Trends and Opportunities
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. France
        • 9.4.5.3.1. Market Trends and Opportunities
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Italy
        • 9.4.5.4.1. Market Trends and Opportunities
        • 9.4.5.4.2. Growth Prospects
      • 9.4.5.5. Spain
        • 9.4.5.5.1. Market Trends and Opportunities
        • 9.4.5.5.2. Growth Prospects
      • 9.4.5.6. Others
        • 9.4.5.6.1. Market Trends and Opportunities
        • 9.4.5.6.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Product Type
    • 9.5.2. By Service Type
    • 9.5.3. By Synthesis Type
    • 9.5.4. By Route of Administration
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Trends and Opportunities
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. UAE
        • 9.5.5.2.1. Market Trends and Opportunities
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Others
        • 9.5.5.3.1. Market Trends and Opportunities
        • 9.5.5.3.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Product Type
    • 9.6.2. By Service Type
    • 9.6.3. By Synthesis Type
    • 9.6.4. By Route of Administration
    • 9.6.5. By Country
      • 9.6.5.1. Japan
        • 9.6.5.1.1. Market Trends and Opportunities
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. China
        • 9.6.5.2.1. Market Trends and Opportunities
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. India
        • 9.6.5.3.1. Market Trends and Opportunities
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Trends and Opportunities
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Taiwan
        • 9.6.5.5.1. Market Trends and Opportunities
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Thailand
        • 9.6.5.6.1. Market Trends and Opportunities
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Indonesia
        • 9.6.5.7.1. Market Trends and Opportunities
        • 9.6.5.7.2. Growth Prospects
      • 9.6.5.8. Others
        • 9.6.5.8.1. Market Trends and Opportunities
        • 9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Sequent Scientific Ltd. (Alivira Animal Health Limited)
  • 11.2. Stanley Black & Decker (Excel Industries Limited)
  • 11.3. Ofichem Group
  • 11.4. Menadiona
  • 11.5. SUANFARMA
  • 11.6. NGL Fine-Chem Ltd.
  • 11.7. FIS - Fabbrica Italiana Sintetici S.p.A.
  • 11.8. Sidhiv Pharma
  • 11.9. Chempro Pharma Private Limited
  • 11.10. AMGIS Lifescience Ltd